vs
CATALYST PHARMACEUTICALS, INC.（CPRX）与Proto Labs Inc（PRLB）财务数据对比。点击上方公司名可切换其他公司
CATALYST PHARMACEUTICALS, INC.的季度营收约是Proto Labs Inc的1.1倍（$152.6M vs $139.3M），CATALYST PHARMACEUTICALS, INC.净利率更高（34.5% vs 5.8%，领先28.7%），Proto Labs Inc同比增速更快（10.4% vs 7.6%），过去两年CATALYST PHARMACEUTICALS, INC.的营收复合增速更高（24.5% vs 5.3%）
Catalyst Pharmaceuticals是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业，专注于罕见病药物研发。核心产品包括用于治疗兰伯特-伊顿肌无力综合征（LEMS）的氨吡啶磷酸盐，商品名为Firdapse。该药物2018年11月获FDA批准，除原有成人适应症外，还可用于6岁及以上的LEMS儿童患者。
Proto Labs是一家提供快速制造服务的企业，可通过3D打印、CNC加工、钣金加工以及注塑成型工艺，为客户生产用于原型制作和量产的定制零部件，产品广泛应用于医疗设备、航空航天、电子、家电、汽车、消费品等多个领域，公司总部位于美国明尼苏达州，在美国多地设有生产基地。
CPRX vs PRLB — 直观对比
营收规模更大
CPRX
是对方的1.1倍
$139.3M
营收增速更快
PRLB
高出2.8%
7.6%
净利率更高
CPRX
高出28.7%
5.8%
两年增速更快
CPRX
近两年复合增速
5.3%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $152.6M | $139.3M |
| 净利润 | $52.7M | $8.1M |
| 毛利率 | 82.9% | 45.6% |
| 营业利润率 | 40.5% | 7.1% |
| 净利率 | 34.5% | 5.8% |
| 营收同比 | 7.6% | 10.4% |
| 净利润同比 | -5.8% | 125.4% |
| 每股收益（稀释后） | $0.40 | $0.29 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CPRXPRLB
| Q1 26 | — | $139.3M | ||
| Q4 25 | $152.6M | $136.5M | ||
| Q3 25 | $148.4M | $135.4M | ||
| Q2 25 | $146.6M | $135.1M | ||
| Q1 25 | $141.4M | $126.2M | ||
| Q4 24 | $141.8M | $121.8M | ||
| Q3 24 | $128.7M | $125.6M | ||
| Q2 24 | $122.7M | $125.6M |
净利润CPRXPRLB
| Q1 26 | — | $8.1M | ||
| Q4 25 | $52.7M | — | ||
| Q3 25 | $52.8M | $7.2M | ||
| Q2 25 | $52.1M | $4.4M | ||
| Q1 25 | $56.7M | $3.6M | ||
| Q4 24 | $55.9M | — | ||
| Q3 24 | $43.9M | $7.2M | ||
| Q2 24 | $40.8M | $4.5M |
毛利率CPRXPRLB
| Q1 26 | — | 45.6% | ||
| Q4 25 | 82.9% | 44.2% | ||
| Q3 25 | 84.7% | 45.3% | ||
| Q2 25 | 85.9% | 44.3% | ||
| Q1 25 | 87.3% | 44.1% | ||
| Q4 24 | 84.7% | 42.7% | ||
| Q3 24 | 85.0% | 45.6% | ||
| Q2 24 | 87.4% | 45.0% |
营业利润率CPRXPRLB
| Q1 26 | — | 7.1% | ||
| Q4 25 | 40.5% | 5.0% | ||
| Q3 25 | 44.7% | 6.5% | ||
| Q2 25 | 45.2% | 3.7% | ||
| Q1 25 | 44.8% | 3.6% | ||
| Q4 24 | 44.3% | -1.2% | ||
| Q3 24 | 39.6% | 6.8% | ||
| Q2 24 | 44.2% | 4.8% |
净利率CPRXPRLB
| Q1 26 | — | 5.8% | ||
| Q4 25 | 34.5% | — | ||
| Q3 25 | 35.6% | 5.3% | ||
| Q2 25 | 35.6% | 3.3% | ||
| Q1 25 | 40.1% | 2.9% | ||
| Q4 24 | 39.4% | — | ||
| Q3 24 | 34.1% | 5.7% | ||
| Q2 24 | 33.2% | 3.6% |
每股收益（稀释后）CPRXPRLB
| Q1 26 | — | $0.29 | ||
| Q4 25 | $0.40 | $0.25 | ||
| Q3 25 | $0.42 | $0.30 | ||
| Q2 25 | $0.41 | $0.18 | ||
| Q1 25 | $0.45 | $0.15 | ||
| Q4 24 | $0.44 | $-0.01 | ||
| Q3 24 | $0.35 | $0.29 | ||
| Q2 24 | $0.33 | $0.18 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $709.2M | $124.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $954.3M | $683.1M |
| 总资产 | $1.1B | $778.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CPRXPRLB
| Q1 26 | — | $124.0M | ||
| Q4 25 | $709.2M | $128.1M | ||
| Q3 25 | $689.9M | $119.2M | ||
| Q2 25 | $652.8M | $103.2M | ||
| Q1 25 | $580.7M | $96.8M | ||
| Q4 24 | $517.6M | $103.1M | ||
| Q3 24 | $442.3M | $100.5M | ||
| Q2 24 | $375.7M | $112.9M |
股东权益CPRXPRLB
| Q1 26 | — | $683.1M | ||
| Q4 25 | $954.3M | $673.9M | ||
| Q3 25 | $920.2M | $664.7M | ||
| Q2 25 | $856.0M | $664.7M | ||
| Q1 25 | $794.3M | $656.8M | ||
| Q4 24 | $727.6M | $670.2M | ||
| Q3 24 | $660.9M | $680.0M | ||
| Q2 24 | $608.7M | $685.2M |
总资产CPRXPRLB
| Q1 26 | — | $778.6M | ||
| Q4 25 | $1.1B | $763.4M | ||
| Q3 25 | $1.1B | $756.9M | ||
| Q2 25 | $971.9M | $743.3M | ||
| Q1 25 | $908.9M | $737.5M | ||
| Q4 24 | $851.4M | $743.5M | ||
| Q3 24 | $772.0M | $753.8M | ||
| Q2 24 | $706.4M | $758.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $44.9M | $17.5M |
| 自由现金流经营现金流 - 资本支出 | $44.9M | — |
| 自由现金流率自由现金流/营收 | 29.4% | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | 0.85× | 2.16× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CPRXPRLB
| Q1 26 | — | $17.5M | ||
| Q4 25 | $44.9M | $16.5M | ||
| Q3 25 | $32.4M | $29.1M | ||
| Q2 25 | $71.3M | $10.6M | ||
| Q1 25 | $60.0M | $18.4M | ||
| Q4 24 | $70.9M | $17.3M | ||
| Q3 24 | $72.9M | $24.8M | ||
| Q2 24 | $64.1M | $14.4M |
自由现金流CPRXPRLB
| Q1 26 | — | — | ||
| Q4 25 | $44.9M | $8.4M | ||
| Q3 25 | — | $25.0M | ||
| Q2 25 | $71.3M | $9.1M | ||
| Q1 25 | — | $17.1M | ||
| Q4 24 | $70.8M | $16.5M | ||
| Q3 24 | $72.6M | $23.2M | ||
| Q2 24 | $64.1M | $10.2M |
自由现金流率CPRXPRLB
| Q1 26 | — | — | ||
| Q4 25 | 29.4% | 6.2% | ||
| Q3 25 | — | 18.5% | ||
| Q2 25 | 48.6% | 6.7% | ||
| Q1 25 | — | 13.6% | ||
| Q4 24 | 49.9% | 13.5% | ||
| Q3 24 | 56.4% | 18.5% | ||
| Q2 24 | 52.3% | 8.2% |
资本支出强度CPRXPRLB
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 5.9% | ||
| Q3 25 | 0.0% | 3.0% | ||
| Q2 25 | 0.0% | 1.1% | ||
| Q1 25 | 0.0% | 1.0% | ||
| Q4 24 | 0.1% | 0.7% | ||
| Q3 24 | 0.2% | 1.2% | ||
| Q2 24 | 0.0% | 3.3% |
现金转化率CPRXPRLB
| Q1 26 | — | 2.16× | ||
| Q4 25 | 0.85× | — | ||
| Q3 25 | 0.61× | 4.03× | ||
| Q2 25 | 1.37× | 2.39× | ||
| Q1 25 | 1.06× | 5.11× | ||
| Q4 24 | 1.27× | — | ||
| Q3 24 | 1.66× | 3.44× | ||
| Q2 24 | 1.57× | 3.18× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPRX
| Firdapse | $97.6M | 64% |
| Agamree | $35.3M | 23% |
| Fycompa | $19.6M | 13% |
PRLB
| CNC Machining | $63.2M | 45% |
| Injection Molding | $51.1M | 37% |
| 3D Printing | $20.5M | 15% |
| Sheet Metal | $4.4M | 3% |
| Other Revenue | $207.0K | 0% |
